A scientific sleuth and a mother who nearly lost her daughter to a hormonal condition teamed up in January to flag a series of papers that misnamed a medication for pregnant women. They have recently started to see the fruits of their labors: one retraction and three corrections.
In 2014, Tara Skopelitis, a lab manager at Cold Spring Harbor Laboratory, was given weekly progesterone injections to prevent preterm birth for her daughter, as reported by STAT. Six years later, after her daughter showed symptoms of an unknown hormonal condition which still hasn’t been formally diagnosed, Skopelitis discovered she should have received synthetic progesterone variant 17α-hydroxyprogesterone caproate, often referred to as 17-OHPC, 17P, sold as Makena. When the drug wasn’t available, her doctor had ordered the wrong replacement from a compounding pharmacy. Skopelitis suspects her daughter’s condition could be a result of the mixup.
The confusion lies within the literature, Skopelitis says: Many clinical trials and papers refer to 17P as intramuscular progesterone, as if they are interchangeable or even the same compound.
Continue reading First paper retracted in string of studies using the wrong medication name